Innovative Collaboration in Mental Health Treatment
This groundbreaking drug combination therapy aims to improve both safety and effectiveness in the fields of mental health and addiction care.
SciSparc Ltd. (Nasdaq: SPRC), a prominent specialty clinical-stage pharmaceutical company, has recently announced the filing of an international patent application together with Clearmind Medicine Inc. (Nasdaq: CMND), a biotechnology firm dedicated to creating groundbreaking therapeutic solutions.
Developing Transformative Therapies
The partnership focuses on a trailblazing combination of Ibogaine and N-Acylethanolamines, aimed at tackling significant challenges in mental health.
Ibogaine is extracted from the root of the Tabernanthe iboga plant, which primarily grows in Western and Central Africa. This compound is known for its potential effectiveness in treating various substance use disorders, including those related to opioids and cocaine. Promising outcomes from human clinical trials underscore Ibogaine's potential as an effective anti-addiction treatment.
Ongoing Research and Patent Filings
As this collaboration progresses and seeks to develop innovative therapeutic options, both SciSparc and Clearmind are concentrating on blending psychedelic molecules with N-Acylethanolamines, such as Palmitoylethanolamide. So far, Clearmind has filed thirteen patents related to this partnership with agencies such as the U.S. Patent and Trademark Office.
Why Ibogaine?
Research suggests that Ibogaine could have significant effects in the fight against addiction. Its unique characteristics represent a crucial shift in confronting chronic issues tied to substance use disorders.
The Role of N-Acylethanolamines
N-Acylethanolamines are naturally occurring lipid compounds recognized for their neuroprotective benefits. Including these in treatment could improve both the safety and effectiveness of the protocols being investigated by SciSparc and Clearmind.
About SciSparc Ltd. and Clearmind Medicine Inc.
SciSparc Ltd. operates in the clinical pharmaceutical arena, concentrating on developing therapies for conditions that impact the central nervous system. Its promising drug development initiatives target Tourette Syndrome, Alzheimer's disease, and autism.
Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company focused on creating therapeutic solutions for common health challenges like alcohol use disorder. The company is building its intellectual property portfolio, which includes nineteen patent families with 29 granted patents, and is actively seeking additional patents as necessary.
Investor Relations and Contact Information
SciSparc is dedicated to open communication and transparency with its investors. For any inquiries, investors can directly contact the company. For more information, interested individuals can email IR@scisparc.com or call +972-3-6167055.
Frequently Asked Questions
What is the main focus of SciSparc's collaboration with Clearmind?
The collaboration mainly focuses on creating innovative therapies that combine Ibogaine with N-Acylethanolamines to address issues related to mental health and addiction.
What are N-Acylethanolamines?
N-Acylethanolamines are lipid compounds that possess neuroprotective properties. They are being investigated alongside Ibogaine to enhance therapeutic effects.
How does Ibogaine work in treating addiction?
Ibogaine appears to treat various substance use disorders by impacting brain chemistry, potentially alleviating withdrawal symptoms and reducing cravings.
How many patents have been filed in connection with this collaboration?
Thirteen patents concerning the SciSparc and Clearmind collaboration have been filed with applicable patent authorities.
What other conditions is SciSparc targeting with its therapies?
SciSparc is also focused on developing treatments for Tourette Syndrome, Alzheimer's disease, and autism, with an emphasis on innovative cannabinoid-based solutions.
